Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
BAY 43-9006
20
CHF
CHF 20.00
In stock
AG-CR1-0025-M0011 mgCHF 20.00
AG-CR1-0025-M0055 mgCHF 55.00
AG-CR1-0025-M02525 mgCHF 160.00
| Product Details | |
|---|---|
| Synonyms | Sorafenib; N-[4-Chloro-3-(trifluoromethyl)phenyl]-([4-[2-(N-methylcarbamoyl)(4-pyridyloxy)]phenyl]amino)-carboxamide |
| Product Type | Chemical |
| Properties | |
| Formula |
C21H16ClF3N4O3 |
| MW | 464.8 |
| CAS | 284461-73-0 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO, 100% ethanol, methanol or ethyl acetate. |
| Identity | Determined by 1H-NMR. |
| InChi Key | MLDQJTXFUGDVEO-UHFFFAOYSA-N |
| Smiles | CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Antitumor compound [1].
- Broad-spectrum kinase inhibitor [2].
- Raf kinase inhibitor [2, 3].
- Apoptosis inducer [3, 4].
- Cytostatic [5].
- Angiogenesis inhibitor [2, 5].
- Review [6].
Product References
- BAY 43-9006: preclinical data: S. Wilhelm & D.S. Chien; Curr. Pharm. Des. 8, 2255 (2002)
- Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature: L. Adnane, et al.; Meth. Enzymol. 407, 597 (2005)
- The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells: D.J. Panka, et al.; Cancer Res. 66, 1611 (2006)
- The kinase inhibitor Sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress: M. Rahmani, et al.; Mol. Cell. Biol. 27, 5499 (2007)
- BAY-43-9006 Bayer/Onyx: J.T. Lee & J.A. McCubrey; Curr. Opin. Investig. Drugs 4, 757 (2003)
- Sorafenib (BAY 43-9006): review of clinical development: R. Ng & E.X. Chen; Curr. Clin. Pharmacol. 1, 223 (2006)